Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1972 1
1975 1
1976 2
1977 3
1978 3
1979 2
1981 2
1983 1
1984 1
1985 1
1986 1
1987 4
1988 5
1989 5
1990 1
1991 5
1992 3
1993 8
1994 14
1995 11
1996 7
1997 15
1998 15
1999 16
2000 14
2001 19
2002 15
2003 27
2004 39
2005 28
2006 29
2007 37
2008 45
2009 48
2010 32
2011 51
2012 43
2013 49
2014 47
2015 42
2016 41
2017 38
2018 35
2019 29
2020 30
2021 22
2022 21
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

796 results

Results by year

Filters applied: . Clear all
Page 1
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Fujiwara N, et al. Among authors: kumada h. Sci Transl Med. 2022 Jun 22;14(650):eabo4474. doi: 10.1126/scitranslmed.abo4474. Epub 2022 Jun 22. Sci Transl Med. 2022. PMID: 35731891 Free PMC article.
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. Yamashita T, et al. Among authors: kumada h. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. J Gastroenterol. 2020. PMID: 31720835 Free PMC article. Clinical Trial.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Among authors: kumada h. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Finn RS, et al. Among authors: kumada h. J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. J Clin Oncol. 2020. PMID: 32716739 Free PMC article. Clinical Trial.
Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.
Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G, Schwartz ME, Kobayashi M, Kumada H, Berger M, Pappo O, Rajewsky K, Hoshida Y, Karin M, Heikenwalder M, Ben-Neriah Y, Pikarsky E. Finkin S, et al. Among authors: kumada h. Nat Immunol. 2015 Dec;16(12):1235-44. doi: 10.1038/ni.3290. Epub 2015 Oct 26. Nat Immunol. 2015. PMID: 26502405 Free PMC article.
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Hoshida Y, et al. Among authors: kumada h. Cancer Res. 2009 Sep 15;69(18):7385-92. doi: 10.1158/0008-5472.CAN-09-1089. Epub 2009 Sep 1. Cancer Res. 2009. PMID: 19723656 Free PMC article.
Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.
Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Yamaoka K, et al. Among authors: kumada h. Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101799. doi: 10.1016/j.clinre.2021.101799. Epub 2021 Sep 7. Clin Res Hepatol Gastroenterol. 2022. PMID: 34500120 Free article.
Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development.
Qian T, Fujiwara N, Koneru B, Ono A, Kubota N, Jajoriya AK, Tung MG, Crouchet E, Song WM, Marquez CA, Panda G, Hoshida A, Raman I, Li QZ, Lewis C, Yopp A, Rich NE, Singal AG, Nakagawa S, Goossens N, Higashi T, Koh AP, Bian CB, Hoshida H, Tabrizian P, Gunasekaran G, Florman S, Schwarz ME, Hiotis SP, Nakahara T, Aikata H, Murakami E, Beppu T, Baba H, Rew Warren, Bhatia S, Kobayashi M, Kumada H, Fobar AJ, Parikh ND, Marrero JA, Rwema SH, Nair V, Patel M, Kim-Schulze S, Corey K, O'Leary JG, Klintmalm GB, Thomas DL, Dibas M, Rodriguez G, Zhang B, Friedman SL, Baumert TF, Fuchs BC, Chayama K, Zhu S, Chung RT, Hoshida Y. Qian T, et al. Among authors: kumada h. Gastroenterology. 2022 Apr;162(4):1210-1225. doi: 10.1053/j.gastro.2021.12.250. Epub 2021 Dec 22. Gastroenterology. 2022. PMID: 34951993 Free PMC article.
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.
Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. Fujiwara N, et al. Among authors: kumada h. Med. 2021 Jul 9;2(7):836-850.e10. doi: 10.1016/j.medj.2021.03.017. Epub 2021 Apr 21. Med. 2021. PMID: 34318286 Free PMC article.
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors.
Akuta N, Kawamura Y, Fujiyama S, Nakamichi K, Saegusa E, Ogura H, Kato M, Doi E, Inoue N, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Suzuki Y, Kumada H, Suzuki F. Akuta N, et al. Among authors: kumada h. Hepatol Res. 2023 Jul;53(7):607-617. doi: 10.1111/hepr.13897. Epub 2023 Mar 17. Hepatol Res. 2023. PMID: 36891614
796 results